-
Ixazomib, daratumumab and low-dose dexamethasone in intermediate-fit patients with newly diagnosed multiple myeloma: an open-label phase 2 trial
Groen, K., Stege, C. A. M., Nasserinejad, K., de Heer, K., van Kampen, R. J. W., Leys, R. B. L., Thielen, N., Westerman, M., Wu, K-L., Ludwig, I., Issa, D. E., Velders, G. A., Vekemans, M-C., Timmers, G-J., de Boer, F., Tick, L. W., Verbrugge, A., Buitenhuis, D., Cunha, S. M., van der Spek, E., & 9 others , 1 Sept 2023, In: EClinicalMedicine. 63, 102167.Research output: Contribution to journal › Article › Academic › peer-review
-
The Dutch CAR-T Tumorboard Experience: Population-Based Real-World Data on Patients with Relapsed or Refractory Large B-Cell Lymphoma Referred for CD19-Directed CAR T-Cell Therapy in The Netherlands
on behalf of the Dutch CAR-T Tumorboard Consortium, 1 Sept 2023, In: Cancers. 15, 17, 4334.Research output: Contribution to journal › Article › Academic › peer-review
-
Evidence-based mechanisms of synergy with IMiD agent-based combinations in multiple myeloma
Neri, P. & Nijhof, I., 1 Aug 2023, In: Critical Reviews in Oncology/Hematology. 188, 104041.Research output: Contribution to journal › Review article › Academic › peer-review
- All publications